Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir

Journal of Clinical Virology

Volumn 47, Issue 1, 2010, Pages 76-78

  Suzuki, Fumitaka ^a   Suzuki, Yoshiyuki ^a   Akuta, Norio ^a   Sezaki, Hitomi ^a   Yatsuji, Hiromi ^a   Arase, Yasuji ^a   Hirakawa, Miharu ^a   Kawamura, Yusuke ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Saito, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Watahiki, Sachiyo ^a   Mineta, Rie ^a   Iwasaki, Satomi ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Hepatitis C virus; Protease inhibitor; Sustained virological response; Telaprevir

Indexed keywords

TELAPREVIR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CLINICAL TRIAL; GENE SEQUENCE; HEPATITIS C; HUMAN; MALE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

AMINO ACID SEQUENCE; EVOLUTION, MOLECULAR; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; SEQUENCE ALIGNMENT; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 72049125601     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.09.029     Document Type: Article

References (19)

1. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
2. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
3. Akuta N., Suzuki F., Kawamura Y., Yatsuji H., Sezaki H., Suzuki Y., et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46 (2007) 403-410
4. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
5. Lin C., Kwong A.D., and Perni R.B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 6 (2006) 3-16
6. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., Vliet A.V., Rooij JVDWD, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase 1b, placebo-controlled, randomized study. Gastroentrology 131 (2006) 997-1002
7. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Muh U., Welker M., et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroentrology 132 (2007) 1767-1777
8. Lawitz E., Rodriguez-Torres M., Muir A.J., Kieffer T.L., McNair L., Khunvichai A., et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 49 (2008) 163-169
9. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360 (2009) 1827-1838
10. Hezode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 360 (2009) 1839-1850
11. Ogata S., Florese R.H., Nagano-Fujii M., Hidajat R., Deng L., Ku Y., et al. Identification of hepatitis C virus (HCV) subtype 1b strains that are highly, or only weakly, associated with hepatocellular carcinoma on the basis of the secondary structure of an amino-terminal portion of the HCV NS3 protein. J Clin Microbiol 41 (2003) 2835-2841
12. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A.M., Young S.K., et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48 (2008) 1769-1778
13. Bartels D.J., Zhou Y., Zhang E.Z., Marcial M., Byrn R.A., Pfeiffer T., et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naïve subjects. JID 198 (2008) 800-807
14. Cubero M., Esteban J.I., Otero T., Sauleda S., Bes M., Esteban R., et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370 (2008) 237-245
15. Franco S., Parera M., Aparicio E., Clotet B., and Martinez M.A. Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology 45 (2007) 899-910
16. Foy E., Li K., Wang C., Surnpter Jr. R., Ikeda M., Lemon S.M., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 (2003) 1145-1148
17. Johnson C.L., Owen D.M., and Gale Jr. M. Functional and therapeutic analysis of hepatitis C virus NS3-4A protease control of antiviral immune defense. J Biol Chem 282 (2007) 10792-10803
18. Loo Y.M., Owen D.M., Li K., Erickson A.K., Johnson C.L., Fish P.M., et al. Viral and therapeutic control of IFN-β promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 103 (2006) 6001-6006
19. Liang Y., Ishida H., Lenz O., Lin T.I., Nyanguile O., Simmen K., et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroentrology 135 (2008) 1710-1718